Top

International Journal of Clinical Oncology

Published in:

01-06-2011 | Original Article

Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma

Authors: Kazuhiro Kasai, Akira Ushio, Yukiho Kasai, Kei Sawara, Yasuhiro Miyamoto, Kanta Oikawa, Hidekatsu Kuroda, Yasuhiro Takikawa, Kazuyuki Suzuki

Published in: International Journal of Clinical Oncology | Issue 3/2011

Abstract

Background

This study evaluated the efficacy of combined 5-fluorouracil (5-FU) and pegylated interferon (PEG-IFN) α-2b in patients with advanced hepatocellular carcinoma (HCC).

Methods

Fifty patients with portal vein tumor thrombosis were enrolled. Of these, 21 patients were treated using subcutaneous administration of PEG-IFNα-2b and intra-arterial infusion of 5-FU (5-FU/PEG-IFN group), 12 patients were treated using intramuscular administration of IFNα-2b and intra-arterial infusion of 5-FU (5-FU/IFN group), and 17 patients received intra-arterial infusion chemotherapy with lipiodol-cisplatin (CDDP) suspension (CDDP group).

Results

The objective early response rate was significantly higher in the 5-FU/PEG-IFN group than in the 5-FU/IFN or CDDP groups (71.4 vs. 8.3% and 17.6%, respectively; P < 0.0001). Cumulative survival rates at 6 and 12 months were 83.8 and 77.8% in the 5-FU/PEG-IFN group, 60.8 and 16.2% in the 5-FU/IFN group, and 58.4 and 12.5% in the CDDP group, respectively. The cumulative survival rate was significantly higher in the 5-FU/PEG-IFN group than in the other 2 groups (P = 0.0272). Serious complications and treatment-related deaths were not observed in any of the 3 groups.

Conclusion

Although a prospective randomized controlled trial using a larger population of patients with advanced HCC is needed to evaluate combination therapy with 5-FU and PEG-IFNα-2b, this new combination therapy may be useful for patients with advanced HCC.

EI-Serag HB, Mason A (1999) Rising incidence of hepatocellular carcinoma in United States. N Engl J Med 340:745–750CrossRef

Okuda K, Fujimoto I, Hanai A et al (1987) Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 47:4967–4972PubMed

La Vecchia C, Lucchini F, Franceschi S et al (2000) Trends in mortality from primary liver cancer in Europe. Eur J Cancer 36:909–915PubMedCrossRef

Ohtomo K, Furui S, Kokubo T et al (1985) Transcatheter arterial embolization (TAE) in treatment for hepatoma-analysis of three-year survivors. Radiat Med 3:176–180PubMed

Shiina S, Tagawa K, Unuma T et al (1990) Percutaneous ethanol injection therapy for treatment of hepatocellular carcinoma. Am J Roentgenol 154:947–951

Shiina S, Teratani T, Obi S et al (2002) Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 62(Suppl 1):64–68 (Review)PubMedCrossRef

Stehlin JS Jr, de Ipolyi PD, Greeff PJ et al (1988) Treatment of cancer of the liver: twenty years’ experience with infusion and resection in 414 patients. Ann Surg 208:23–35PubMedCrossRef

Ono Y, Yoshimasu T, Ashikaga R et al (2000) Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23:564–568PubMed

Yoshikawa M, Ono N, Yodono H et al (2008) Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38:474–483PubMedCrossRef

10.

Sakon M, Nagano H, Dono K et al (2002) Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94:435–442PubMedCrossRef

11.

Obi S, Yoshida H, Toune R et al (2006) Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 106:1990–1997PubMedCrossRef

12.

Glue P, Fang JW, Rouzier-Panis R et al (2000) Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 68:556–567PubMedCrossRef

13.

Kasai K, Kuroda H, Ushio A et al (2009) Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. Hepatol Res 39:117–125PubMedCrossRef

14.

Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef

15.

Liver Cancer Study Group of Japan (2000) The general rules for the clinical and pathological study of primary liver cancer, 4th edn. Kanehara, Tokyo, p 19 (in Japanese)

16.

Irie T (2001) Intraarterial chemotherapy of liver metastasis: implantation of microcatheter-port system with use of modified fixed catheter tip technique. J Vasc Interv Radiol 12:1215–1218PubMedCrossRef

17.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef

18.

NCI Common Toxicity Criteria. Common terminology criteria for adverse events v3.0 (CTCAE). Cited 9 August 2006. Available from: http://ctep.cancer.gov/reporting/ctc.html

19.

Fujii T, Takayasu K, Muramatsu Y et al (1993) Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 23:105–109PubMed

20.

Chen SC, Hsieh MY, Chuang WL et al (1994) Development of portal vein invasion and its outcome in hepatocellular carcinoma treated by transcatheter arterial chemo-embolization. J Gastroenterol Hepatol 9:1–6PubMedCrossRef

21.

Schwartz EL, Hoffman M, O’Connor CJ et al (1992) Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun 182:1232–1239PubMedCrossRef

22.

Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50:3473–3486PubMed

23.

Elias L, Sandoval JM (1989) Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163:867–874PubMedCrossRef

24.

Kondo M, Nagano H, Wada H et al (2005) Combination of IFN-α and 5-fluorouracil induces apoptosis through IFN-α/β receptor in human hepatocellular carcinoma cells. Clin Cancer Res 11:1277–1286PubMedCrossRef

25.

Yano H, Iemura A, Haramaki M et al (1999) Interferon alfa receptor expression and growth inhibition by interferon alpha in human liver cell lines. Hepatology 29:1708–1717PubMedCrossRef

26.

Silva M, Poo J, Wagner F et al (2006) A randomized trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 45:204–213PubMedCrossRef

27.

Drewinko B, Yang L-Y (1985) Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Res 69:1391–1398

28.

Guchelaar HJ, Vermes I, Koopmans RP et al (1998) Apoptosis-and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol 42:77–83PubMedCrossRef

29.

Ueshima K, Tatsumi C, Sakaguchi Y et al (2006) Breakthrough of the hepatic arterial infusion chemotherapy of hepatocellular carcinoma. Gastroenterology (Tokyo) 43:253–259 (in Japanese)

30.

Okada S, Okazaki N, Nose H et al (1992) Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology 16:112–117PubMedCrossRef

31.

Uka K, Aikata H, Takaki S et al (2007) Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 42:845–853PubMedCrossRef

32.

Kantoh T, Abo H, Tomotsu K et al (1993) Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization (TAE)––significance of repetitive therapies and responses to them within 6 months after the first intervention. Nippon Shokakibyo Gakkai Zasshi 90:1416–1424 (in Japanese)PubMed

33.

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390PubMedCrossRef

Title: Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma
Authors: Kazuhiro Kasai
Akira Ushio
Yukiho Kasai
Kei Sawara
Yasuhiro Miyamoto
Kanta Oikawa
Hidekatsu Kuroda
Yasuhiro Takikawa
Kazuyuki Suzuki
Publication date: 01-06-2011
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 3/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-010-0151-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2011

Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor

The role of lymph node dissection in renal cell carcinoma

Role of lymph node dissection in management of bladder cancer

High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin

Polyostotic fibrous dysplasia with gigantism and huge pelvic tumor: a rare case of McCune–Albright syndrome

Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer